Table 3 Association between hyperactivity sub-syndromes with AD biomarkers and CSVD markers in whole sample

Age

0.014 (-0.028, 0.056)

0.508

-

-

-

-

Sex

1.395 (0.752, 2.037)

<0.001

-

-

-

-

Education

-0.154 (-0.276, -0.031)

0.014

-

-

-

-

APOE ε4 carrier status

-0.164 (-0.818, 0.490)

0.623

-

-

-

-

Clinical diagnosis

1.269 (0.562, 1.976)

<0.001

-

-

-

-

Aβ₄₂ (pg/ml)

-0.001 (-0.008, 0.005)

0.666

0.002 (-0.006, 0.009)

0.682

-

-

p-tau₁₈₁ (pg/ml)

0.005 (-0.006, 0.017)

0.350

0.005 (-0.007, 0.016)

0.422

-

-

t-tau (pg/ml)

0.001 (-0.004, 0.007)

0.627

0.001 (-0.005, 0.007)

0.716

-

-

p-tau₁₈₁/Aβ₄₂

0.800 (-0.507, 2.107)

0.230

0.690 (-0.709, 2.088)

0.333

-

-

t-tau/Aβ₄₂

0.153 (-0.463, 0.769)

0.626

0.116 (-0.562, 0.794)

0.737

-

-

PVL-WMH score

0.108 (-0.281, 0.497)

0.586

0.108 (-0.330, 0.546)

0.628

-

-

DWM-WMH score

0.001 (-0.378, 0.378)

1.000

-0.031 (-0.444, 0.382)

0.883

-

-

BG-PVS score

-0.314 (-1.028, 0.401)

0.389

-0.312 (-1.005, 0.382)

0.377

-

-

CSO-PVS score

-0.216 (-0.641, 0.210)

0.320

-0.103 (-0.521, 0.315)

0.628

-

-

Microbleeds

1.127 (0.278, 1.976)

0.009

0.934 (0.144, 1.724)

0.021

0.925 (0.115, 1.735)

0.025

Lacune

0.726 (-0.098, 1.551)

0.084

0.585 (-0.236, 1.406)

0.162

-

-